PharmEasy just sold another slice of Thyrocare. It may be the last one.

In today's Article, we talk about a promoter who's been carving up a perfectly good business to pay off a loan — and why the final slice might be the one that sets the whole thing free.

In June 2021, an Indian startup did something no Indian startup had done before.

API Holdings — the parent of PharmEasy — bought a listed company.

Not a stake. Not a strategic partnership. Control. It picked up 66.1% of Thyrocare Technologies, India's best-known B2B diagnostics chain, for ₹4,546 crore. The price? ₹1,300 a share. And it did this through a wholly-owned subsidiary with a rather forgettable name — Docon Technologies.

At the time it looked like the future. An online pharmacy buying a pathology lab network. Medicines plus diagnostics, all under one app. PharmEasy was a unicorn, money was cheap, and IPO bankers were already sharpening their pencils.

Then the music stopped.

The IPO never happened. Funding dried up. PharmEasy's valuation was slashed in later rounds by a brutal margin. And API Holdings was left holding something it hadn't fully planned for — debt.

Which brings us to Thursday.

On 13 August, Docon sold 1,57,69,696 shares of Thyrocare. That's 9.9% of the company, worth roughly ₹986 crore. Around 1.31 crore of those shares went through the block deal window at ₹624 apiece — a near 3% discount to the previous close — snapped up by a queue of buyers including Citigroup, Morgan Stanley and HSBC Mutual Fund.

Thyrocare's stock did what stocks do when a promoter dumps 10%. It fell nearly 8% intraday.

And here's the thing. This isn't the first time.

Rewind to October 2025. Docon sold about 10% of Thyrocare then too — around ₹668 crore worth. Promoter holding went from 70.98% to 60.93%.

Now it's gone from 60.92% to 51.02%.

Two sales. Two years. Roughly ₹1,650 crore raised. And a promoter stake that has quietly slid from two-thirds of the company to barely over half.

If you're wondering why a company would keep selling a business that's actually doing rather well — and Thyrocare is doing well, we'll get to that — the answer sits in a boring little word that appears in every exchange filing about this saga.

Pledge.

When API Holdings needed money, it did what borrowers with few options do. It offered up the best thing it owned.

Docon pledged its entire 9,69,69,696-share holding in Thyrocare as security. First against an expensive high-double-digit loan from Goldman Sachs. Then, in 2025, API refinanced that with ₹1,690 crore of high-yield bonds sold to corporate treasuries at a blended yield of about 12.8% — cheaper than the Goldman facility, and with a gentler pledge requirement of "just over 60%" instead of 100%.

Cheaper. But still expensive. And still ₹1,050 crore of non-convertible debentures sitting there, accruing interest, needing to be repaid.

So look at what happened in the week of the sale, in order:

11 August: Catalyst Trusteeship, the debenture trustee, releases the pledge on 1,75,00,000 Thyrocare shares — about 11% of the company. Docon's shareholding doesn't change at all. Only the encumbrance does.

13 August: Docon sells 1,57,69,696 shares.

You don't release a pledge on 1.75 crore shares out of goodwill. You release it because those shares are about to be sold, and you can't sell what's locked up.

Even after all this, roughly 7.94 crore Thyrocare shares — nearly 50% of the entire company — remain encumbered.

Read that again. Half of a listed, profitable, well-run diagnostics company is sitting as collateral for its owner's borrowings.

Yes. That's the strange part.

Thyrocare just reported a rather good quarter. For Q1 FY27, revenue rose 24% year-on-year to ₹240 crore. Profit after tax jumped 34% to ₹51 crore. EBITDA also grew 34%, to ₹77 crore. It processed 55.2 million tests, up 28%.

The stock had rallied about 37% this year while the Sensex fell 8.5%.

So this is not a distressed sale of a bad asset. It's a healthy asset being sold because it's healthy — because it's the one thing on API's balance sheet that a Citigroup or an HSBC Mutual Fund will happily write a cheque for at short notice.

Which is a slightly uncomfortable position for a company to be in. Thyrocare's share price now carries information that has nothing to do with thyroid tests or collection centres or lab automation. It carries information about its parent's repayment schedule.

Now, if you've read this far, you've probably concluded this is a sad story. Startup overreaches, startup sells the family silver, repeat until nothing's left.

Except the company tells it differently. And its version is worth hearing, because it explains why this particular sale might be the last one.

Thyrocare's MD and CEO Rahul Guha has laid out what the group is actually working towards — and it's not survival. It's a reverse merger.

The idea is roughly this. PharmEasy still needs to become a listed company somehow. It can list independently. Or it can fold into something already listed — and API Holdings happens to control a company that is already listed, already profitable, and already trades on the exchanges. Thyrocare.

But before anyone even discusses that, two conditions have to be met.

One: the group has to be debt-free. Which, going by Guha, is now a matter of days — once the proceeds from this very stake sale land. That ₹986 crore isn't a partial repayment or a refinancing. It's meant to close the book on the ₹1,050 crore of NCDs entirely.

Two: API Holdings has to be profitable at the pre-tax level — excluding Thyrocare. That's the harder one, and it's the honest one. No propping up the parent's numbers with the subsidiary's profits. PharmEasy and the rest of the group have to stand on their own. Guha expects this by the end of FY27, and reckons PharmEasy could turn profitable within the next three or four quarters.

Only after both boxes are ticked does the company sit down and weigh its options — independent listing, reverse merger, or something else entirely.

Which reframes Thursday rather nicely.

Because if the debt genuinely goes to zero, then that 49.93% pledge overhang goes to zero with it. And a promoter that isn't pledging its shares to lenders has no reason to keep selling them. The stake sales stop not because there's nothing left to sell, but because there's nothing left to repay.

Two numbers.

51.02% — the promoter stake today. Still comfortably majority control. But it's now close enough to the line that any further sale becomes a genuinely different kind of decision.

Zero — the group's debt, if the plan holds. This is the one that matters. Everything in this story, going back to 2021, has been downstream of that number.

There's also a quiet piece of good news buried in here for minority shareholders. Every one of these sales expands the free float. Mutual funds already own close to 20% of Thyrocare; institutions have queued up eagerly for each block. A more widely held, more liquid Thyrocare, with no pledge hanging over it, is a better stock than a tightly held one shackled to its parent's loan book. Which is probably why the shares have kept climbing between these sales rather than sinking.

But hold the confetti.

A reverse merger, if it ever happens, means Thyrocare shareholders wake up owning a piece of PharmEasy too. And PharmEasy is a very different animal — a loss-making e-pharmacy in a market where Amazon, Tata and Reliance are all circling. You'd be swapping a clean, boring, 34%-profit-growth diagnostics business for a conglomerate with a consumer internet company attached.

Some shareholders will love that. Others bought Thyrocare precisely to avoid it.

Either way, the story's about to change shape. For five years, Thyrocare has been the asset that kept the parent alive. If Guha's timeline holds, it's about to become the vehicle the parent climbs into.

Sometimes the most interesting company in the story is the one that wasn't doing anything interesting at all.

Until next time…

The numbers, quickly

Note: headlines reported both 8.9% and 9.9% — the smaller figure reflects only the portion routed through the exchange block deal window with named counterparties. The full disclosed sale was 9.90%.

This is not investment advice. Please do your own research.